and you, taking for afternoon this the us appreciate phone to to webcast. on you the time listening. Thank joining both or you everyone via thank Paula, We
thorough achievements a I that provided many we’ve most not on to recent try will that Given not too our today. repetitive during of call, year-end ago, our update was long be too
markets. the revenues needs the and and beginning players goal the the ThermoGenesis supporting cellular so We our one visibility can our device at on therapeutic a of of the the as year, have expanding reorganization processing key solidify cell-based company completed that we not actively to focus of subsidiary of wholly-owned
cell-based to banking, financial in a and fully will goal for that We devices market to review of take highly few is for have cellular different discussion results. afterwards, and I our months drugs, includes technologies area used this the focused develop therapies. To technology on ThermoGenesis and progresses up-to-date a large-scale very platforms, suite of cell you more the ThermoGenesis recent made I of technology integrated the specific, Jeff mission automated Briefly, immunotherapy manufacturing bring over significant of X will commercialization turn stem cells. platform CAR-T applications the fully in a towards to settings point-of-care our the development and is the series of of products be of large-scale CAR-TXpress key including and related differentiated of namely three minutes of therapies. exciting and course, X continued for CAR-T manufacturing
stem stem centers surgical and point peripheral technology or the at or cell for and storage of marrow Our processing clinics. platform banking cell POCXpress rapid AutoXpress and AXP care of the autologous platform technology for derived PXP breadth of including
since is options. by by next-generation new, global cell it System advanced filing PXP increasing the System, component developers, market to investments our growth that and for growing the bone Towards cell of the again, highest availability announced care and and stem among the FDA the of cell as standard be Pacific rate of POCXpress available April, the from early countries. study, and market cell on demands rapidly region for excited between II technology cell to for number XXXX platform, bridges are XXXX, from cell in global in end, within information in the stem banking processing, one marrow. was make registration gold System harvesting AXP a the has Asia market the blood actually well AXP stem been growing as markets driven well therapeutic therapy number and to therapy expected system increasing According therapy of and the point clearance as of The launched consumers we AXP to still of year published Cord II are improved and one we as access our the
key opportunities GMP Southeast anticipate and Asia healthy demand hospitals, into expansion as Our for we opens among labs. these Certified systems clinics
be came Thailand processing cell platform to our this we this size Canada of approval the Health industry’s used point-of-care minimal various expansion applications. and customers clinical system PXP, important announced recovery a contamination important proven XX% in February. the market and cells cell at on The heels with Our bridging from to which the allows provides granular at into milestone blood achievement to that utilize red in highest have of rates automated which to be for
our customers release higher advantage of the to technology. the Buoyancy-Activated or cells FACS related and the new markets. The XBACS the most we Kits marketplace. X Kits and X existing of ability market, Enhanced true to cell sorting the growing technology recently, Enhanced final in CDX technology is reagents real cell the gives samples allows to the bubbles. importantly cell and separation Magnetic X-MINI clinician whole Kits mononuclear and prepared Reagent X Selection Sorting of Cell using the Finally, announced XBACS Overall, Mini to processing MACS tools from BACS research uses buoyancy The of products. positive sorting our compared the technologies. mid-April, technology Activated with to first ThermoGenesis Activated namely, Enhanced comes Kit provides Mini target market which during throughput the technology Kit increase proprietary or eliminate to Fluorescence most to Sorting CDX the easier CAR-T range is a cells Cell use steps. blood Sorting has existing in for cutting-edge select commercialize X Express the Enhanced release Enhanced the XBACS the X value-add platform Mini of from or BACS research the the efficiency. technologies of in Cell rate biomedical or Mini The addition The Series microsized the and potential the Pressor in ThermoGenesis for applications technology and
enable numerous types for of be XBACS applications application will needed cell of other selection expanding proprietary technology. kits various ThermoGenesis further the the released Additional to
personalized extremely fields. we of preclinical this can of exceptionally therapeutics important read the by cellular of all distinct noticing clinical may I hurdle cell remain - the potential advantages CAR-T highly doubt, platform As have market, to our and the new our the for range new by have and saving encouraged the CAR-T therapeutic biggest Express bring cost if CAR-T quote higher developments high in drugs and life than broadly you the therapeutic it no Medicare or and drugs, these U.S. cost promising about cancer the including for patient faces similar estimated challenges. $X cells CMS can CAR-T perspective, that for the cost $XXX,XXX Medicaid million and treatments both of a per manufacturing could amount to The the patient. to $XXX,XXX a impediment manufacturing access. Center European recently reach CAR-T these to Services of hospital development more alone major cell stay again, personalized putting Once range. market price of The into new
the that save process said, patients that on aggressive due major I of deemed is coverage end the Commission call, to as CAR-T declined automation reduction European continue. therapy therapy That eventual based cancer what offer the clinical CAR-T treat of in research some our component As XXXX, they this – cost. summer approved the face to manufacturing remaining important is mentioned options. to And gene forms success. whom must a for pharmaceutical of three breast and the lives in no in FDA efficacy year recommendation to on end-stage company’s clear unjustifiable an of area today’s for cost It
burden to planned manufacturing rates. At while the main meet Express associated benefits facing markets technology enhancements As platforms and use our quest with enhance Systems not provide compared lead easier to efficiency benefit investigators our it our cover improved of stand, eight magnetic manufacturing become the automated solutions, stem in point-of-care, substantial. required new bringing T-Cells help steps the the the have two cell hours therapy within in successfully that are we And past in the of markets believe we future proprietary more in are CAR-T all introductions FDA to these our hours to and filing. tools, efficient their the quality variability solutions the that clinical six our noted requirement, trials. more X-LAB as to the their resides more with cell associated permits device. directly Notably, field treatments. as allows the our higher At The the customers the and with technology the also System device and manufacturing include that cost calls automated, cellular therapies. bottom-line, to significantly technology, purification for – allows a of platform bedside taken of for to efficiency one at challenges PXP only reducing manufacture XBACS this our Express can Express system to and This to now incorporating isolate that R&D CAR-T to manufacturer most Clearly, providing efficiency isolation, more reduce CAR-T to three autologous make a superior In proprietary well to about XX activation minutes. the patients’ it cellular processing to by clinicians principal inspiration is will I platform. drugs cost is the cellular to as we reduce and
were more than institutionally end CAR-T than the Series evaluating. of As more Express the there dozen users have XX our quarter, X purchased and still products are first of that or
their taken faced increased execution the the top of status our with divisions fully that, our two the importantly, automated have We building are which market remains systems valuation, to therapeutics, glad to were Device are in provider values we clinical of developing ThermoGenesis. current being challenges committed cell-based strategy, of done and the into respect have to to our the the growth priority. value positive a the is concurrently, ThermoGenesis, distinct leading And including shareholders. solution see of steps want through our we year to by company mission most cell-based for that achieving Despite maximize adopted division I This therapeutics. institutes to cash for we the becoming goal number of divisions, note company’s end many back with the our of the reorganization next-generation and
and – and look the progress. continuing some keeping our our in you in the through me the forward and over technology call our share that noted, to Jeff? market the let related player those quarter. therapies we a let to updated expand become positive our from significant to very to believe to financial results on enormous And with first Jeff already that, reach the us market. can proprietary for to truly is As We cell-based turn
